These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18657103)

  • 1. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany.
    McBride D; Mattenklotz AM; Willich SN; Brüggenjürgen B
    Value Health; 2009; 12(2):293-301. PubMed ID: 18657103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Atrial fibrillation in Germany: A prospective cost of illness study].
    Spyra A; Daniel D; Thate-Waschke IM; Berghaus S; Willich S; Zeymer U; Rychlik R
    Dtsch Med Wochenschr; 2015 Jul; 140(14):e142-8. PubMed ID: 26182263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of practice patterns in the treatment of atrial fibrillation among the commercially insured.
    Liu J; Sylwestrzak G; Barron J; Rosenberg A; White J; Whitney J; Redberg R; Malenka D
    Curr Med Res Opin; 2014 Sep; 30(9):1707-13. PubMed ID: 24809834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.
    Poulin F; Khairy P; Roy D; Levesque S; Talajic M; Guertin JR; Lelorier J;
    Can J Cardiol; 2013 Oct; 29(10):1256-62. PubMed ID: 23751149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France.
    Cotté FE; Chaize G; Kachaner I; Gaudin AF; Vainchtock A; Durand-Zaleski I
    J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e73-83. PubMed ID: 24119623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.
    Catherwood E; Fitzpatrick WD; Greenberg ML; Holzberger PT; Malenka DJ; Gerling BR; Birkmeyer JD
    Ann Intern Med; 1999 Apr; 130(8):625-36. PubMed ID: 10215558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study).
    Zoni-Berisso M; Filippi A; Landolina M; Brignoli O; D'Ambrosio G; Maglia G; Grimaldi M; Ermini G
    Am J Cardiol; 2013 Mar; 111(5):705-11. PubMed ID: 23273528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy.
    Aronsson M; Walfridsson H; Janzon M; Walfridsson U; Nielsen JC; Hansen PS; Johannessen A; Raatikainen P; Hindricks G; Kongstad O; Pehrson S; Englund A; Hartikainen J; Mortensen LS; Levin LÅ
    Europace; 2015 Jan; 17(1):48-55. PubMed ID: 25341739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of rhythm versus rate control in atrial fibrillation.
    Marshall DA; Levy AR; Vidaillet H; Fenwick E; Slee A; Blackhouse G; Greene HL; Wyse DG; Nichol G; O'Brien BJ;
    Ann Intern Med; 2004 Nov; 141(9):653-61. PubMed ID: 15520421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
    Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource utilization and outcomes in patients with atrial fibrillation: a case control study.
    Boggon R; Lip GY; Gallagher AM; van Staa TP
    Appl Health Econ Health Policy; 2012 Jul; 10(4):249-59. PubMed ID: 22540235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study.
    Hagens VE; Vermeulen KM; TenVergert EM; Van Veldhuisen DJ; Bosker HA; Kamp O; Kingma JH; Tijssen JG; Crijns HJ; Van Gelder IC;
    Eur Heart J; 2004 Sep; 25(17):1542-9. PubMed ID: 15342174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital.
    Allen Lapointe NM; Sun JL; Kaplan S; d'Almada P; Al-Khatib SM
    Am J Cardiol; 2008 Apr; 101(8):1134-41. PubMed ID: 18394447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
    Amin AN; Jhaveri M; Lin J
    Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study.
    Opolski G; Torbicki A; Kosior D; Szulc M; Zawadzka M; Pierścińska M; Kołodziej P; Stopiński M; Wozakowska-Kapłon B; Achremczyk P; Rabczenko D
    Kardiol Pol; 2003 Jul; 59(7):1-16; discussion 15-16. PubMed ID: 14560344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy.
    Kim MH; Lin J; Hussein M; Battleman D
    Curr Med Res Opin; 2009 Dec; 25(12):3037-47. PubMed ID: 19852699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation.
    Kim MH; Klingman D; Lin J; Pathak P; Battleman DS
    Ann Pharmacother; 2009 May; 43(5):840-8. PubMed ID: 19417111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Atrial fibrillation--epidemiologic, economic and individual burden of disease].
    Brüggenjürgen B; Reinhold T; McBride D; Willich SN
    Dtsch Med Wochenschr; 2010 Mar; 135 Suppl 2():S21-5. PubMed ID: 20221974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study.
    Brüggenjürgen B; Rossnagel K; Roll S; Andersson FL; Selim D; Müller-Nordhorn J; Nolte CH; Jungehülsing GJ; Villringer A; Willich SN
    Value Health; 2007; 10(2):137-43. PubMed ID: 17391422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation.
    Eckman MH; Falk RH; Pauker SG
    Arch Intern Med; 1998 Aug 10-24; 158(15):1669-77. PubMed ID: 9701102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.